Anaplastic Astrocytoma - Pipeline Review, H2 2016

Date: November 9, 2016
Pages: 118
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: ABA0598F129EN
Leaflet:

Download PDF Leaflet

Anaplastic Astrocytoma - Pipeline Review, H2 2016
Anaplastic Astrocytoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma – Pipeline Review, H2 2016, provides an overview of the Anaplastic Astrocytoma (Oncology) pipeline landscape.

Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among men and women in their thirties to fifties and is more common in men than women. Treatment of anaplastic astrocytoma depends on the location of the tumor and how far it has progressed and usually involves surgery and radiation therapy, with chemotherapy during or following radiation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaplastic Astrocytoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaplastic Astrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 3, 7 and 7 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 2 molecules, respectively.Anaplastic Astrocytoma.

Anaplastic Astrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Anaplastic Astrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anaplastic Astrocytoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anaplastic Astrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anaplastic Astrocytoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anaplastic Astrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Anaplastic Astrocytoma Overview
Therapeutics Development
Pipeline Products for Anaplastic Astrocytoma - Overview
Pipeline Products for Anaplastic Astrocytoma - Comparative Analysis
Anaplastic Astrocytoma - Therapeutics under Development by Companies
Anaplastic Astrocytoma - Therapeutics under Investigation by Universities/Institutes
Anaplastic Astrocytoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Anaplastic Astrocytoma - Products under Development by Companies
Anaplastic Astrocytoma - Products under Investigation by Universities/Institutes
Anaplastic Astrocytoma - Companies Involved in Therapeutics Development
AngioChem Inc.
Astellas Pharma Inc.
Axelar AB
Boehringer Ingelheim GmbH
Burzynski Research Institute, Inc.
Cavion LLC
Celldex Therapeutics, Inc.
Millennium Pharmaceuticals Inc
Novartis AG
Orbus Therapeutics, Inc.
Pfizer Inc.
Tocagen Inc.
TVAX Biomedical, Inc.
Anaplastic Astrocytoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
afatinib dimaleate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alisertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antineoplaston Therapy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AXL-1717 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bendamustine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CDX-1401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Gliomas - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNX-2401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eflornithine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flucytosine + TBio-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flucytosine ER + vocimagene amiretrorepvec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
irinotecan hydrochloride + TBio-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-032 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mibefradil dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nilotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
p28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
paclitaxel trevatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palbociclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TVI-Brain-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anaplastic Astrocytoma - Dormant Projects
Anaplastic Astrocytoma - Discontinued Products
Anaplastic Astrocytoma - Product Development Milestones
Featured News & Press Releases
Sep 26, 2016: Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer
Dec 07, 2015: Burzynski Research Institute Announces Favorable Objective Response Rates and Overall Survival in Adults with Anaplastic Astrocytoma Following Antineoplastons A-10 and AS2-1
Jun 18, 2015: Burzynski Research Institute Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Anaplastic Astrocytoma, H2 2016
Number of Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Anaplastic Astrocytoma - Pipeline by AngioChem Inc., H2 2016
Anaplastic Astrocytoma - Pipeline by Astellas Pharma Inc., H2 2016
Anaplastic Astrocytoma - Pipeline by Axelar AB, H2 2016
Anaplastic Astrocytoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Anaplastic Astrocytoma - Pipeline by Burzynski Research Institute, Inc., H2 2016
Anaplastic Astrocytoma - Pipeline by Cavion LLC, H2 2016
Anaplastic Astrocytoma - Pipeline by Celldex Therapeutics, Inc., H2 2016
Anaplastic Astrocytoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Anaplastic Astrocytoma - Pipeline by Novartis AG, H2 2016
Anaplastic Astrocytoma - Pipeline by Orbus Therapeutics, Inc., H2 2016
Anaplastic Astrocytoma - Pipeline by Pfizer Inc., H2 2016
Anaplastic Astrocytoma - Pipeline by Tocagen Inc., H2 2016
Anaplastic Astrocytoma - Pipeline by TVAX Biomedical, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Anaplastic Astrocytoma - Dormant Projects, H2 2016
Anaplastic Astrocytoma - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Anaplastic Astrocytoma, H2 2016
Number of Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Anaplastic Astrocytoma - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: